Roadmap towards an institutional Impella programme for high‐risk coronary interventions

Coronary artery disease (CAD) and its complications remain the main cause of morbidity and mortality worldwide. Patients with extensive CAD and multiple comorbidities who require complex, high‐risk percutaneous coronary intervention (HR‐PCI) are at risk of haemodynamic instability and may require short‐term mechanical circulatory support (MCS) during the procedure to maintain sufficient perfusion and prevent ischaemia. Impella is a microaxial continuous blood flow pump used for percutaneous support of the left ventricle in patients undergoing HR‐PCI. Data from randomized controlled trials and registries suggested an advantage for Impella devices in patients undergoing HR‐PCI, compared with other types of MCS. As a thorough understanding of the benefits and drawbacks of the Impella technology is crucial for patient outcomes, we provide a technological overview of Impella and share our experiences gathered during the implementation of institutional Impella programmes in Poland as a roadmap of selection and periprocedural care for patients treated with Impella in the setting of HR‐PCI. We propose 10 steps for implementation of an institutional Impella programme for HR‐PCI, including (i) dedicated staff training; (ii) standard operating procedure and troubleshooting algorithms prior to the first intervention; (iii) patient selection by the multidisciplinary Heart Team; (iv) patient preparation using multimodality imaging; (v) procedure planning in terms of large‐bore access, equipment, and complete revascularization; (vi) starting with HR‐PCI support; (vii) starting with femoral artery access in a patient without extensive peripheral artery disease; (viii) multidisciplinary care after the procedure; (ix) haemodynamic and laboratory monitoring to ensure immediate diagnosis of access‐site complications, bleeding, haemolysis, acute kidney injury, and infections; and (x) careful revision of every HR‐PCI case with the team.